Clinical research is already full of challenges — COVID-19 added a new layer of complexity.

The global pandemic forced the industry to quickly deploy innovative strategies to ensure that clinical trials continued with minimal disruption. Learn more about how we evolved our overall approach to meet the moment, from diabetes to oncology and beyond.

In times of uncertainty, we evolved our approach to ensure business continuity for our customers' clinical trials:

Maintaining Momentum:

COVID-19 forced us to move forward with new ways to advance cardiovascular trials. By rapidly deploying innovative tactics, along with the trust of our customers, we ensured patients remained active in ongoing studies to meet key timelines and deliver with unwavering success. Watch more below:

Sensitivity to Strategies:

When a large diabetes trial in China was facing obstacles to patient recruitment and engagement as a result of lockdown, we had to carefully select the right strategy to overcome them. With a combination of proactive project management and cultural understanding, we exceeded site enrollment rates by 40%. Read more.

Patients as Priority:

Even under normal conditions, engaging oncology patients in clinical research is a challenge. COVID-19 made it obvious that there was a need for easier clinical trial participation. With the use of innovative, patient-centric digital solutions, we were able to significantly decrease patient burden. Listen to the full story.